IGHE and chronic idiopathic urticaria: Approved options to treat humans affected by chronic spontaneous urticaria (CSU) are antihistamines in up to a fourfold dosage and an anti-IgE monoclonal antibody, omalizumab, which have demonstrated efficacy, however, not in all patient groups [16,18].